<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616196</url>
  </required_header>
  <id_info>
    <org_study_id>19-255-03</org_study_id>
    <nct_id>NCT04616196</nct_id>
  </id_info>
  <brief_title>Study of NKTR 255 in Combination With Cetuximab in Solid Tumors</brief_title>
  <official_title>A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR 255 in Combination With Cetuximab as a Salvage Regimen for Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or&#xD;
      colorectal carcinoma (CRC) will receive a loading dose of cetuximab alone, followed 7 days&#xD;
      later by the first combination treatment of cetuximab and NKTR-255 on Cycle 1 Day 1 (C1D1).&#xD;
      Thereafter, intravenous (IV) NKTR-255 will be given in 21-day cycles in combination with&#xD;
      weekly IV cetuximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255&#xD;
      in combination with cetuximab, this dose of NKTR-255 will be further studied in patients with&#xD;
      HNSCC (Cohort A) and CRC (Cohort B) in Phase 2 of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 1b/2, open-label, multicenter dose escalation and dose expansion study&#xD;
      in patients with R/R HNSCC or CRC.&#xD;
&#xD;
      NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation,&#xD;
      proliferation and promote their anti-tumor effects.&#xD;
&#xD;
      After an initial cetuximab loading dose during the study run-in period (Day -7), patients&#xD;
      will receive IV NKTR-255 every 21 days in combination with cetuximab weekly. In the dose&#xD;
      escalation phase, beginning with Dose Level 1, successive cohorts will receive ascending&#xD;
      doses of NKTR-255 until the MTD and/or RP2D is determined. Patients who achieve optimal&#xD;
      response (partial response or complete response), will be given the option to continue&#xD;
      treatment with NKTR-255 as single agent for maintenance.&#xD;
&#xD;
      Enrollment into Phase 2 will commence once the RP2D is established in Phase 1b. The RP2D of&#xD;
      NKTR-255 will be evaluated in expansion Cohorts A and B. Cohort A will combine NKTR-255 and&#xD;
      cetuximab in patients with R/R HNSCC and Cohort B will combine NKTR-255 and cetuximab in&#xD;
      patients with R/R CRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1: Dose escalation cohorts will be sequential Phase 2: Cohorts A and B will be in parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 with Cetuximab</measure>
    <time_frame>60 days after the last dose of study treatment.</time_frame>
    <description>Safety and tolerability of NKTR-255 in combination with cetuximab as evaluated by dose limiting toxicities, incidence of drug-related Adverse Events (AEs), SAEs, and AEs leading to discontinuation, deaths, and clinical laboratory abnormalities per CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of NRTR-255 with Cetuximab</measure>
    <time_frame>Through study completion, an expected average of 1 year</time_frame>
    <description>Efficacy of NKTR-255 in combination with cetuximab in R/R metastatic HNSCC or CRC by assessing the objective response rate (ORR) by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of NKTR-255 with Cetuximab</measure>
    <time_frame>Through study completion, an expected average of 1 year</time_frame>
    <description>Evaluate the anti-tumor activity of the combination of NKTR-255 and cetuximab by assessing progression-free survival (PFS) and overall survival (OS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma (HNSCC)</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <arm_group>
    <arm_group_label>Dose Escalation of NKTR-255 with Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Establish RP2D, of NKTR-255 with cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion of NKTR-255 with Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The RP2D of NKTR-255 will be evaluated in expansion Cohorts A and B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-255</intervention_name>
    <description>After the loading dose of cetuximab, NKTR-255 IV, every 21 days with cetuximab weekly.</description>
    <arm_group_label>Dose Escalation of NKTR-255 with Cetuximab</arm_group_label>
    <other_name>Cetuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-255</intervention_name>
    <description>Cohort A will combine NKTR-255 and cetuximab in patients with R/R HNSCC and Cohort B will combine NKTR-255 and cetuximab in patients with R/R CRC. Each cycle of NKTR-255 will be 21 days, and cetuximab will be given weekly.</description>
    <arm_group_label>Dose expansion of NKTR-255 with Cetuximab</arm_group_label>
    <other_name>Cetuximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of a locally advanced or metastatic HNSCC or CRC.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks as determined by the Investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1.&#xD;
&#xD;
        HNSCC: Progression on any first or second line platinum-based chemotherapy and/or anti-PD-1&#xD;
        or programmed death-ligand 1 antibody.&#xD;
&#xD;
        CRC: Patients must have received or were intolerant to at least 2 prior cancer therapy&#xD;
        regimens administered for metastatic disease.&#xD;
&#xD;
        CRC: Patients with microsatellite instability-high (MSI-H) or mismatched repair disease&#xD;
        (dMMR) tumors must have been exposed to checkpoint inhibitors such as anti-PD-(L)1 or&#xD;
        anticytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of an investigational agent or an investigational device within 28 days before&#xD;
             administration of first dose of study drug(s)&#xD;
&#xD;
          -  Prior surgery or radiotherapy within 14 days of initiating study drug(s)&#xD;
&#xD;
          -  Evidence of clinically significant interstitial lung disease or active, noninfectious&#xD;
             pneumonitis; active infection requiring systemic therapy within 7 days prior to dosing&#xD;
&#xD;
          -  Patients who have been previously treated with IL-2 or IL-15&#xD;
&#xD;
          -  Contraindication to or unable to receive cetuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nektar Recruitment</last_name>
    <phone>855-482-8676</phone>
    <email>medicalaffairs@nektar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Affairs</last_name>
    <email>medicalaffairs@nektar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Health Care</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Center for Cancer Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>CRC</keyword>
  <keyword>R/R</keyword>
  <keyword>NKTR-255</keyword>
  <keyword>Cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

